Skip to main content

Stephen Joseph Balevic

Associate Professor of Pediatrics
Pediatrics, Rheumatology
2301 Erwin Rd, Durham, NC 27710
2301 Erwin Rd, Durham, NC 27710

Overview


I am an Adult and Pediatric Rheumatologist and care for patients with a wide variety of autoimmune and rheumatic diseases, including: systemic lupus, rheumatoid arthritis, juvenile arthritis, vasculitis, and sarcoidosis, among others. I have a special interest in using musculoskeletal ultrasound to optimize diagnosis and treatment decisions at the bedside.

I am also a clinical researcher at the Duke Clinical Research Institute (DCRI). My research interests are in clinical trials and precision medicine through population pharmacokinetic/pharmacodynamic modeling. I obtained my PhD in Pharmaceutical Sciences from the UNC Eshelman School of Pharmacy. I serve as the principal investigator on several grants studying hydroxychloroquine and azathioprine pharmacokinetics and exposure-response in lupus, as well as principal investigator or co-investigator for several clinical trials at the DCRI. Additionally, I am an Assistant Scientific Director for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry- the largest registry of children with rheumatic diseases in North America.

Current Appointments & Affiliations


Associate Professor of Pediatrics · 2022 - Present Pediatrics, Rheumatology, Pediatrics
Associate Professor of Medicine · 2022 - Present Medicine, Rheumatology and Immunology, Medicine
Member in the Duke Clinical Research Institute · 2018 - Present Duke Clinical Research Institute, Institutes and Centers

In the News


Published September 22, 2020
DCRI Launches First Direct-to-Family Study

View All News

Recent Publications


Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants.

Journal Article J Clin Pharmacol · April 2026 Furosemide is the most commonly used diuretic in preterm infants despite an incompletely understood relationship between dosing, exposure, and safety within this population. The goals of this study were to characterize furosemide population pharmacokinetic ... Full text Link to item Cite

Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity.

Journal Article Clin Pharmacokinet · February 2026 BACKGROUND: Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body w ... Full text Link to item Cite
View All Publications

Recent Grants


PTN 3.0 Task Order #2_ BPCA Pediatric Drug Development Clinical Trial Infrastructure

ResearchProject Leader · Awarded by National Institutes of Health · 2025 - 2030

Induced Suppression of Platelet Activity in Aneurysmal SAH Management-2 (iSPASM-2)

Clinical TrialInvestigator · Awarded by National Institutes of Health · 2025 - 2030

Pharmacokinetic Modeling to Optimize Dosing in Pediatric Rheumatic Diseases

ResearchPrincipal Investigator · Awarded by Thrasher Research Fund · 2025 - 2028

View All Grants

Education


University of North Carolina, Chapel Hill · 2022 Ph.D.
Duke University, School of Medicine · 2018 M.H.S.
Marshall University · 2010 M.D.